← All trials
NCT05020184
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 31, 2021
- Primary completion
- Feb 28, 2025
- Completion date
- Sep 30, 2025
- First posted
- Aug 25, 2021
- Last posted
- Aug 25, 2021
- Enrollment
- 20
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Harvard UniversityLead sponsor
- Harvard UniversityOverall official - principal investigator
- Harvard UniversitySponsor investigator
- Wake Forest UniversityCollaborator
- University of Texas, GalvestonCollaborator
- University of Texas, GalvestonOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.